aXichem (AXIC-A.ST) Stock Analysis & AI Equity Report
aXichem (AXIC-A.ST) overview
aXichem (AXIC-A.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, aXichem reported revenue of SEK 18.4m and operating profit of SEK -16.9m; the year-end share price was 2.07 SEK and market capitalisation was SEK 123m. aXichem is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get aXichem's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About aXichem
aXichem develops, patents and markets nature-analog industrial chemicals, with phenylcapsaicin as its main product. It sells the ingredient under the brands aXiphen and aXivite for poultry feed and dietary supplements, and also targets applications in gut health, weight control, sports nutrition, and bio-enhancement of curcumin and melatonin.
Generate the aXichem report
aXichem is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for aXichem and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on aXichem
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.